One-year outcomes from INFINITY-SWEDEHEART RCT recently presented at ESC 2024 demonstrated that DynamX Bioadaptor meets primary endpoint and significantly reduces adverse events compared to DES after six months. Dr David Erlinge, the primary investigator of INFINITY-SWEDEHEART RCT, shares a quick summary of the one-year outcomes presented at ESC 2024. He highlights how the novel design and mechanism of action of DynamX Bioadaptor restores haemodynamic modulation to the artery, delivers sustained significant clinical benefit at six months, establishing a new therapy and potentially a new standard of treatment for patients with CAD.¹

References:

1. Dr Erlinge INFINITY-SWEDEHEART RCT 1-year. ESC 2024.